MedPath

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Completed
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
Registration Number
NCT01536639
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
454
Inclusion Criteria
  • Subjects with type 2 diabetes
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
BIAsp 30 usersbiphasic insulin aspart 30-
Primary Outcome Measures
NameTimeMethod
HbA1c (glycosylated haemoglobin)
Secondary Outcome Measures
NameTimeMethod
Weight
Hypoglycaemia
Adverse events
Fasting plasma glucose (FPG)
Post-prandial glucose (PPG)

Trial Locations

Locations (1)

Novo Nordisk Investigational Site

🇸🇰

Bratislava, Slovakia

Novo Nordisk Investigational Site
🇸🇰Bratislava, Slovakia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.